Myant acquires mmHg Inc. to enhance precision medicine for cardiovascular care

Myant Corp., a provider of chronic disease prevention through precision medicine, announced the acquisition of mmHg Inc., a digital health company specializing in remote blood pressure monitoring, cardiovascular risk reduction and chronic disease management. This acquisition expands Myant’s market reach to the USA, where mmHg has an existing customer base, including a partnership with A&D Medical, a manufacturer of medical devices and health products.

mmHg’s platform provides care for managing cardiovascular health, particularly in remote settings. Health care providers can remotely track and analyze blood pressure and a spectrum of vital cardiovascular indicators through its software. Institutions across North America, such as Harvard Medical, Johns Hopkins, Columbia University, New York University, Tulane University, and the University of British Columbia, currently use the platform.

By combining mmHg’s advanced remote monitoring capabilities with Myant’s material and textile computing technology, health care providers will have access to continuous, real-time patient data, enabling earlier detection of health risks, personalized treatment plans and better management of chronic conditions. The result is early disease detection that improves health outcomes, reduces hospital visits and enhances the quality of life.

“Our company is on a mission to make healthy aging a reality for millions. We want to turn the tide on chronic conditions and redefine what it means to grow older. This acquisition enhances our ability to offer comprehensive cardiovascular monitoring and risk management solutions, strengthening our role in transforming digital health and enabling this large aging demographic to live younger, longer,” says Tony Chahine, CEO at Myant.

“The combination of Myant’s cutting-edge textile technology and mmHg’s clinically-infused software architecture will no doubt create the next generation of personalized care-delivery, where patients will be able to transmit clinical-grade, continuous vitals data feeds to a platform that presents the data in an efficient and clinically relevant manner to care teams,” said Peter Wood, co-founder and COO at mmHg Inc.

This acquisition aligns with Myant’s ongoing efforts to leverage AI and advanced materials to improve patient outcomes and extend human life.